The capacity of the immune system to control cancer

European Journal of Cancer

Volumn 45, Issue 12, 2009, Pages 2068-2070

  Håkansson, Leif ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE;

ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CHRONIC INFLAMMATION; DRUG RESPONSE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR IMMUNITY;

EID: 67650925669     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.002     Document Type: Note

References (25)

1. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
2. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
3. Cochran A.J., Morton D.L., Stern S., et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14 (2001) 604-608
4. Schüle J., Bergkvist L., Håkansson L., Gustafsson B., and Håkansson A. Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat 74 (2002) 33-40
5. Schüle J.M., Bergkvist L., Håkansson L., Gustafsson B., and Håkansson A. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J Transl Med 2 (2004) 45
6. Wolfram R.M., Budinsky A.C., Brodowicz T., et al. Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 88 (2000) 239-244
7. Petersen R.P., Campa M.J., Sperlazza J., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 (2006) 2866-2872
8. Atreya I., and Neurath M.F. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 8 4 (2008) 561-572
9. Nelson B.H. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222 (2008) 101-116
10. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7 (2007) 4
11. Ruffini E., Asioli S., Filosso P.L., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 87 (2009) 365-371
12. Yu P., and Fu Y.X. Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest 86 (2006) 231-245
13. Perrone G., Ruffini P.A., Catalano V., et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 44 (2008) 1875-1882
14. Bates G.J., Fox S.B., Han C., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (2006) 5373-5380
15. Wolf D., Wolf A.M., Rumpold H., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11 (2005) 8326-8331
16. Hodi F.S., Butler M., Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105 (2008) 3005-3010
17. Clinchy B., Fransson A., Druvefors B., et al. Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma. Cancer 109 (2007) 1742-1749
18. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
19. Teng M.W., Swann J.B., Koebel C.M., Schreiber R.D., and Smyth M.J. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 84 (2008) 988-993
20. Håkansson A., Gustafsson B., Krysander L., et al. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer 85 (2001) 1871-1877
21. Håkansson A., Gustafsson B., Krysander L., and Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74 (1996) 670-676
22. Donskov F., Bennedsgaard K.M., Von Der Maase H., et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 87 (2002) 194-201
23. Louahed J., Gruselle O., Gaulis S., et al. J Clin Oncol 26 (2008) abstract 9045
24. Yu P., Lee Y., Liu W., et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201 (2005) 779-791
25. Nielsen M.B., and Marincola F.M. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother Pharmacol 46 Suppl. (2000) S62-S66